Loading...
•
Jun 30, 2021
Amgen Q2 2021 Earnings Report
Amgen's financial performance in Q2 2021 reflected a recovery from pandemic effects, marked by volume-driven growth and strategic pipeline advancements.
Key Takeaways
Amgen reported a 5% increase in total revenues to $6.5 billion for Q2 2021, driven by higher unit demand. GAAP EPS decreased 73% to $0.81, influenced by a $1.5 billion write-off related to acquired IPR&D. Non-GAAP EPS increased 4% to $4.38, bolstered by revenue growth and fewer shares outstanding. The company reaffirmed its full-year revenue guidance and revised GAAP EPS guidance.
Total revenues increased by 5% to $6.5 billion, driven by higher unit demand.
GAAP EPS decreased 73% to $0.81 due to a write-off of acquired IPR&D.
Non-GAAP EPS increased 4% to $4.38, supported by revenue growth and fewer shares outstanding.
Free cash flow was $1.7 billion, impacted by the timing of tax payments.
Amgen
Amgen
Amgen Revenue by Segment
Amgen Revenue by Geographic Location
Revenue by Segment
Repatha Revenue
CapyFin.comEVENITY Revenue
CapyFin.comProlia Revenue
CapyFin.comOtezla Revenue
CapyFin.comEnbrel Revenue
CapyFin.comKyprolis Revenue
CapyFin.comXGEVA Revenue
CapyFin.comVectibix Revenue
CapyFin.comNplate Revenue
CapyFin.comBLINCYTO Revenue
CapyFin.comAranesp Revenue
CapyFin.comParsabiv Revenue
CapyFin.comAMJEVITA / AMGEVITA Revenue
CapyFin.comMVASI Revenue
CapyFin.comNeulasta Revenue
CapyFin.comOther products Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Amgen reaffirmed its total revenue guidance for 2021 to be in the range of $25.8 billion to $26.6 billion. The company revised its GAAP EPS guidance to $8.84-$9.90 and reaffirmed its non-GAAP EPS guidance to $16.00-$17.00.
Positive Outlook
- Total revenues are expected to be in the range of $25.8 billion to $26.6 billion.
- Non-GAAP EPS is projected to be between $16.00 and $17.00.
- Capital expenditures are estimated to be approximately $900 million.
- Share repurchases are expected to be at the upper end of the $3.0 billion to $5.0 billion range.
- Tax rate on a non-GAAP basis is expected to be in the range of 13.5% to 14.5%.
Challenges Ahead
- GAAP EPS is projected to be between $8.84 and $9.90.
- Tax rate on a GAAP basis is expected to be in the range of 13.0% to 14.5%.
- The cumulative decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continue to impact our business during the second half of the year.
- Expect further reduction in the net selling price on a sequential basis as the number of Medicare Part D patients receiving Repatha increases.
- Going forward, we expect net selling price for Enbrel to continue to decline year-over-year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income